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System-wide adoption of Personalised Healthcare
requires an active and flexible but highly integrated
infrastructure, joining many different competences and
technologies and allowing continuous upgrading, also
through self-learning processes. In this system, clinics
and diagnostics would no longer be partitioned, accord-
ing to a stepwise scheme, from other disciplines as basic
science, information technologies, ethics and policies.
Each player constitutes a node of a cabled network,
where input and output from each node are automati-
cally transferred to all nodes, to systematically retune
and coordinate the global activity. Since 2005 the San-
t’Andrea Hospital of Rome is an in-house built model of
Personalised Healthcare Service, which auto-catalytically
drives its own development, which may furnish good
evidence that translation of Personalised Medicine into
clinical practice is not so elusive. The interaction
between usually distant academic departments and
wards (as Biochemistry, Internal Medicine, Psychiatry,
Oncology), favoured by a farsighted management of hos-
pital resources by the administrators, allowed to create a
shared, innovative laboratory, the Advanced Molecular
Diagnostics Unit (DiMA). The availability of advanced
technologies, as mass spectrometry and medium-to-high
throughput DNA analysis paved the way to a “real-time”
evaluation of the benefits brought into the “real-world”
clinical practice by implementation of new diagnostics
aimed to therapy tailoring. This allowed the start up of
a health service based on the principles of personalised
medicine, in order to optimize the amount of tests
necessary to evaluate the patient, to interpret the results
correctly and, finally, to plan a personalised therapy and
to periodically evaluate and/or modify it, to obtain the
best clinical results with the least side effects.
Our OMICS platform for personalised medicine offers
the following combined approaches:
i) Epigenetics, to obtain information on the regulation
of gene expression and to evaluate the methylation pro-
file change during hypomethylation therapies;
ii) Functional genomics, to measure genetic expression
in normal and pathologic conditions, in order to define
genetic expression profiles;
iii) Structural genomics, which defines genomic differ-
ences with clinical impact in the patient populations;
iv) Metabolomics and terapeutic drug managment, to
define all molecules of interest in a specific clinical con-
text and the actual drug and metabolite concentration
during therapies.
The MIFAR (Metabolismo Integrato FARmaci – drug
metabolism integration) including about 60 gene variants
has been developed. The data interpretation is ruled out
using the Charité Bioinformatic platform (Berlin DE) and
allows adaptation of drug therapies to the individual
MIFAR profile, improving efficacy and safety of treat-
ments. The DiMA Unit provides pharmacogenomics and
theranostics report for at least 5,000 patients/year.
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